Bioassays for target screening and drug profiling

The identification of a specific biological target is the first step in the drug discovery process. The drug then needs to be developed for this target.

BRAIN Group company AnalytiCon Discovery is a qualified and reliable partner in the field of target-to-lead discovery. The growing portfolio for target screening and drug profiling includes state-of-the-art cell-based and biochemical assays for validated or novel therapeutic targets such as G-protein-coupled receptors, protein kinases, ion channels and protein-protein interactions as well as functional and phenotypic approaches.